Neurological Sciences

, Volume 23, Supplement 2, pp s53–s54

Body weight, levodopa pharmacokinetics and dyskinesia in Parkinson's disease

Authors

  • G. Arabia
    • Institute of Neurology, University of Catanzaro, Policlinico Mater Domini, Via T. Campanella, I-88100 Catanzaro, Italy
  • M. Zappia
    • Institute of Neurology, University of Catanzaro, Policlinico Mater Domini, Via T. Campanella, I-88100 Catanzaro, Italy
  • D. Bosco
    • Institute of Neurological Sciences, National Research Council, Piano Lago di Mangone (CS), Italy
  • L. Crescibene
    • Institute of Neurological Sciences, National Research Council, Piano Lago di Mangone (CS), Italy
  • A. Bagalà
    • Institute of Neurological Sciences, National Research Council, Piano Lago di Mangone (CS), Italy
  • L. Bastone
    • Institute of Neurological Sciences, National Research Council, Piano Lago di Mangone (CS), Italy
  • M. Caracciolo
    • Institute of Neurological Sciences, National Research Council, Piano Lago di Mangone (CS), Italy
  • M. Scornaienghi
    • Institute of Neurological Sciences, National Research Council, Piano Lago di Mangone (CS), Italy
  • A. Quattrone
    • Institute of Neurology, University of Catanzaro, Policlinico Mater Domini, Via T. Campanella, I-88100 Catanzaro, Italy

DOI: 10.1007/s100720200066

Cite this article as:
Arabia, G., Zappia, M., Bosco, D. et al. Neurol Sci (2002) 23: s53. doi:10.1007/s100720200066
  • 70 Views

Abstract.

We conducted a pharmacokinetic study in 164 patients with sporadic Parkinson's disease (PD) to address the relationship between body weight and levodopa pharmacokinetics. Patients underwent an oral acute levodopa test with 250 mg levodopa and pharmacokinetic variables were further assessed. Plasmatic levodopa area under the curve (AUC-l) and body weight were significantly and inversely correlated. Women were significantly lighter and more dyskinetic than men, and had greater AUC-l values. Our data suggest that during long-term treatment, lighter PD patients, especially women, may receive a greater cumulative dosage of levodopa per kilogram of body weight. This could explain gender differences for the development of levodopa-induced peak-dose dyskinesias observed during the course of the disease.

Download to read the full article text

Copyright information

© Springer-Verlag Italia 2002